332 related articles for article (PubMed ID: 26749081)
21. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Messiou C; Porta N; Sharma B; Levine D; Koh DM; Boyd K; Pawlyn C; Riddell A; Downey K; Croft J; Morgan V; Stern S; Cheung B; Kyriakou C; Kaczmarek P; Winfield J; Blackledge M; Oyen WJG; Kaiser MF
Radiol Imaging Cancer; 2021 Sep; 3(5):e210048. PubMed ID: 34559006
[TBL] [Abstract][Full Text] [Related]
22. One-stop local and whole-body staging of children with cancer.
Daldrup-Link HE; Theruvath AJ; Baratto L; Hawk KE
Pediatr Radiol; 2022 Feb; 52(2):391-400. PubMed ID: 33929564
[TBL] [Abstract][Full Text] [Related]
23. Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer.
Adeleke S; Latifoltojar A; Sidhu H; Galazi M; Shah TT; Clemente J; Davda R; Payne HA; Chouhan MD; Lioumi M; Chua S; Freeman A; Rodriguez-Justo M; Coolen A; Vadgama S; Morris S; Cook GJ; Bomanji J; Arya M; Chowdhury S; Wan S; Haroon A; Ng T; Ahmed HU; Punwani S
BMC Med Imaging; 2019 Nov; 19(1):90. PubMed ID: 31730466
[TBL] [Abstract][Full Text] [Related]
24. Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
Taylor SA; Mallett S; Miles A; Beare S; Bhatnagar G; Bridgewater J; Glynne-Jones R; Goh V; Groves AM; Janes SM; Koh DM; Morris S; Morton A; Navani N; Oliver A; Padhani AR; Punwani S; Rockall AG; Halligan S
BMC Cancer; 2017 May; 17(1):299. PubMed ID: 28464835
[TBL] [Abstract][Full Text] [Related]
25. DWI-MRI
Berzaczy D; Staudenherz A; Raderer M; Weber M; Mayerhoefer ME
Br J Radiol; 2019 Jan; 92(1093):20180263. PubMed ID: 30040435
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.
Taylor SA; Mallett S; Ball S; Beare S; Bhatnagar G; Bhowmik A; Boavida P; Bridgewater J; Clarke CS; Duggan M; Ellis S; Glynne-Jones R; Goh V; Groves AM; Hameeduddin A; Janes SM; Johnston EW; Koh DM; Lock S; Miles A; Morris S; Morton A; Navani N; Oliver A; O'Shaughnessy T; Padhani AR; Prezzi D; Punwani S; Quinn L; Rafiee H; Reczko K; Rockall AG; Russell P; Sidhu HS; Strickland N; Tarver K; Teague J; Halligan S;
Lancet Respir Med; 2019 Jun; 7(6):523-532. PubMed ID: 31080129
[TBL] [Abstract][Full Text] [Related]
27. Comparison of
Geng H; Li J; Zhang W
Heliyon; 2024 Jan; 10(1):e23922. PubMed ID: 38226231
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients.
de Mooij CM; Sunen I; Mitea C; Lalji UC; Vanwetswinkel S; Smidt ML; van Nijnatten TJA
Nucl Med Commun; 2020 Oct; 41(10):995-1004. PubMed ID: 32769814
[TBL] [Abstract][Full Text] [Related]
29. Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden.
Giles SL; deSouza NM; Collins DJ; Morgan VA; West S; Davies FE; Morgan GJ; Messiou C
Clin Radiol; 2015 Jun; 70(6):614-21. PubMed ID: 25799364
[TBL] [Abstract][Full Text] [Related]
30. Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment.
Miles A; Taylor SA; Evans REC; Halligan S; Beare S; Bridgewater J; Goh V; Janes S; Navani N; Oliver A; Morton A; Rockall A; Clarke CS; Morris S;
Eur Radiol; 2019 Jul; 29(7):3889-3900. PubMed ID: 30937589
[TBL] [Abstract][Full Text] [Related]
31. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging.
Bronstein Y; Ng CS; Rohren E; Ross MI; Lee JE; Cormier J; Johnson VE; Hwu WJ
AJR Am J Roentgenol; 2012 Apr; 198(4):902-8. PubMed ID: 22451559
[TBL] [Abstract][Full Text] [Related]
32. Validation of automated whole-body analysis of metabolic and morphological parameters from an integrated FDG-PET/MRI acquisition.
Guglielmo P; Ekström S; Strand R; Visvanathar R; Malmberg F; Johansson E; Pereira MJ; Skrtic S; Carlsson BCL; Eriksson JW; Ahlström H; Kullberg J
Sci Rep; 2020 Mar; 10(1):5331. PubMed ID: 32210327
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy of diffusion-weighted imaging- magnetic resonance imaging compared to positron emission tomography/computed tomography in evaluating and assessing pathological response to treatment in adult patients with lymphoma: A systematic review.
Fitzpatrick JJ; Ryan MA; Bruzzi JF
J Med Imaging Radiat Oncol; 2018 Mar; ():. PubMed ID: 29577630
[TBL] [Abstract][Full Text] [Related]
34. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review.
Norman G; Fayter D; Lewis-Light K; Chisholm J; McHugh K; Levine D; Jenney M; Mandeville H; Gatz S; Phillips B
BMJ Open; 2015 Jan; 5(1):e006030. PubMed ID: 25573522
[TBL] [Abstract][Full Text] [Related]
35. Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography.
Oprea-Lager DE; Cysouw MCF; Boellaard R; Deroose CM; de Geus-Oei LF; Lopci E; Bidaut L; Herrmann K; Fournier LS; Bäuerle T; deSouza NM; Lecouvet FE
Front Oncol; 2021; 11():772530. PubMed ID: 34869009
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET imaging in hematological malignancies.
Valls L; Badve C; Avril S; Herrmann K; Faulhaber P; O'Donnell J; Avril N
Blood Rev; 2016 Jul; 30(4):317-31. PubMed ID: 27090170
[TBL] [Abstract][Full Text] [Related]
37. Body Diffusion-weighted MR Imaging in Oncology: Imaging at 3 T.
Koh DM; Lee JM; Bittencourt LK; Blackledge M; Collins DJ
Magn Reson Imaging Clin N Am; 2016 Feb; 24(1):31-44. PubMed ID: 26613874
[TBL] [Abstract][Full Text] [Related]
38. Whole body MRI in multiple myeloma: Optimising image acquisition and read times.
Singh S; Pilavachi E; Dudek A; Bray TJP; Latifoltojar A; Rajesparan K; Punwani S; Hall-Craggs MA
PLoS One; 2020; 15(1):e0228424. PubMed ID: 31999774
[TBL] [Abstract][Full Text] [Related]
39. Gamma delta lymphoma: a pictorial review of F-18 fluorodeoxyglucose PET/CT findings and a brief review of the literature.
Rayamajhi SJ; Ponisio MR; Mehta-Shah N
Br J Radiol; 2024 Jan; 97(1153):41-52. PubMed ID: 38263839
[TBL] [Abstract][Full Text] [Related]
40. 18 F-FDG PET/CT in Synovial Anaplastic Large Cell Lymphoma.
Chiu KL; Chow TK; Ma WH; Ma KM
Clin Nucl Med; 2024 Jul; 49(7):666-668. PubMed ID: 38409753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
